These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 12500242

  • 1. Conjugated bile acid replacement therapy reduces urinary oxalate excretion in short bowel syndrome.
    Emmett M, Guirl MJ, Santa Ana CA, Porter JL, Neimark S, Hofmann AF, Fordtran JS.
    Am J Kidney Dis; 2003 Jan; 41(1):230-7. PubMed ID: 12500242
    [Abstract] [Full Text] [Related]

  • 2. Conjugated bile acid replacement therapy in short bowel syndrome patients with a residual colon.
    Kapral C, Wewalka F, Praxmarer V, Lenz K, Hofmann AF.
    Z Gastroenterol; 2004 Jul; 42(7):583-9. PubMed ID: 15248106
    [Abstract] [Full Text] [Related]

  • 3. Enteric-coated cholylsarcosine microgranules for the treatment of short bowel syndrome.
    Fürst T, Bott C, Stein J, Dressman JB.
    J Pharm Pharmacol; 2005 Jan; 57(1):53-60. PubMed ID: 15638993
    [Abstract] [Full Text] [Related]

  • 4. Conjugated bile acid replacement therapy for short-bowel syndrome.
    Gruy-Kapral C, Little KH, Fordtran JS, Meziere TL, Hagey LR, Hofmann AF.
    Gastroenterology; 1999 Jan; 116(1):15-21. PubMed ID: 9869597
    [Abstract] [Full Text] [Related]

  • 5. Bile acid replacement therapy with cholylsarcosine for short-bowel syndrome.
    Heydorn S, Jeppesen PB, Mortensen PB.
    Scand J Gastroenterol; 1999 Aug; 34(8):818-23. PubMed ID: 10499484
    [Abstract] [Full Text] [Related]

  • 6. 'Enteral' hyperoxaluria. Effect of cholestyramine, calcium, neomycin, and bile acids on intestinal oxalate absorption in man.
    Caspary WF, Tönissen J, Lankisch PG.
    Acta Hepatogastroenterol (Stuttg); 1977 Jun; 24(3):193-200. PubMed ID: 883468
    [Abstract] [Full Text] [Related]

  • 7. [Cholysarkosin in treatment of bile acid deficiency syndrome].
    Weinand I, Stein J.
    Z Gastroenterol; 1999 Jul; 37(7):675-7. PubMed ID: 10458016
    [No Abstract] [Full Text] [Related]

  • 8. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats.
    Lorenzo-Zúñiga V, Bartolí R, Planas R, Hofmann AF, Viñado B, Hagey LR, Hernández JM, Mañé J, Alvarez MA, Ausina V, Gassull MA.
    Hepatology; 2003 Mar; 37(3):551-7. PubMed ID: 12601352
    [Abstract] [Full Text] [Related]

  • 9. The urinary response to an oral oxalate load in recurrent calcium stone formers.
    Krishnamurthy MS, Hruska KA, Chandhoke PS.
    J Urol; 2003 Jun; 169(6):2030-3. PubMed ID: 12771711
    [Abstract] [Full Text] [Related]

  • 10. Steatorrhea and Hyperoxaluria in Severely Obese Patients Before and After Roux-en-Y Gastric Bypass.
    Moreland AM, Santa Ana CA, Asplin JR, Kuhn JA, Holmes RP, Cole JA, Odstrcil EA, Van Dinter TG, Martinez JG, Fordtran JS.
    Gastroenterology; 2017 Apr; 152(5):1055-1067.e3. PubMed ID: 28089681
    [Abstract] [Full Text] [Related]

  • 11. Importance of the colon in enteric hyperoxaluria.
    Dobbins JW, Binder HJ.
    N Engl J Med; 1977 Feb 10; 296(6):298-301. PubMed ID: 831127
    [Abstract] [Full Text] [Related]

  • 12. Effect of cimetidine and pancreatic enzymes on serum and fecal bile acids and fat absorption in cystic fibrosis.
    Boyle BJ, Long WB, Balistreri WF, Widzer SJ, Huang N.
    Gastroenterology; 1980 May 10; 78(5 Pt 1):950-3. PubMed ID: 7380201
    [Abstract] [Full Text] [Related]

  • 13. Effect of replacement therapy with cholylsarcosine on fat malabsorption associated with severe bile acid malabsorption. Studies in dogs with ileal resection.
    Longmire-Cook SJ, Lillienau J, Kim YS, Schteingart CD, Danzinger RG, Esch O, Hofmann AF.
    Dig Dis Sci; 1992 Aug 10; 37(8):1217-27. PubMed ID: 1379904
    [Abstract] [Full Text] [Related]

  • 14. Oral L-arginine supplementation ameliorates urinary risk factors and kinetic modulation of Tamm-Horsfall glycoprotein in experimental hyperoxaluric rats.
    Pragasam V, Kalaiselvi P, Sumitra K, Srinivasan S, Varalakshmi P.
    Clin Chim Acta; 2005 Oct 10; 360(1-2):141-50. PubMed ID: 15992786
    [Abstract] [Full Text] [Related]

  • 15. [Nephrolithiasis in patients with intestinal diseases].
    Cirillo M, Iudici M, Marcarelli F, Laudato M, Zincone F.
    G Ital Nefrol; 2008 Oct 10; 25(1):42-8. PubMed ID: 18264917
    [Abstract] [Full Text] [Related]

  • 16. Dietary oxalate and calcium oxalate nephrolithiasis.
    Khan SR, Glenton PA, Byer KJ.
    J Urol; 2007 Nov 10; 178(5):2191-6. PubMed ID: 17870111
    [Abstract] [Full Text] [Related]

  • 17. Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation.
    Penniston KL, Nakada SY.
    Urology; 2009 Mar 10; 73(3):484-9. PubMed ID: 19118878
    [Abstract] [Full Text] [Related]

  • 18. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, Hesse A.
    Am J Kidney Dis; 2005 Sep 10; 46(3):440-5. PubMed ID: 16129205
    [Abstract] [Full Text] [Related]

  • 19. Absorptive hyperoxaluria: a new clinical entity--successful treatment with hydrochlorothiazide.
    Yendt ER, Cohanim M.
    Clin Invest Med; 1986 Sep 10; 9(1):44-50. PubMed ID: 3955921
    [Abstract] [Full Text] [Related]

  • 20. Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status.
    Thamilselvan S, Menon M.
    BJU Int; 2005 Jul 10; 96(1):117-26. PubMed ID: 15963133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.